Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai